18 active not recruiting. 18 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Active not recruiting 18 |
| Phase 2 | 5 | Active not recruiting 5 |
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2020-09-01 | 2026-02-27 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-10-27 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Adavosertib, Olaparib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2020-06-30 | 2026-09-30 |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2019-11-21 | 2026-09-29 |
| Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy Atezolizumab, Niraparib, Quality-of-Life Assessment - Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 59 | 2019-03-06 | 2026-02-12 |
| FID-007 in Treating Participants With Advanced Solid Tumors Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Active not recruiting | University of Southern California | 50 | 2018-05-25 | 2026-04-29 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Cisplatin, Methoxyamine, Pemetrexed Disodium - Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2016-03-08 | 2026-07-31 |
| Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors Cyclophosphamide, Dasatinib, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 14 | 2015-10-05 | 2026-09-25 |
| EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors EphA2-targeting DOPC-encapsulated siRNA, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 49 | 2015-07-01 | 2026-07-21 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Akt Inhibitor MK2206, Hydroxychloroquine - Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2011-11-23 | 2026-09-09 |
| Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Dinaciclib, Veliparib - Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 121 | 2011-11-11 | 2026-08-03 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Laboratory Biomarker Analysis, Pharmacological Study, Riluzole - Advanced Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2011-02-18 | 2026-09-15 |
Neoplasm Metastasis (7) · Melanoma (4) · Ovarian Neoplasms (4) · Lung Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Renal Cell (2) · Fallopian Tube Neoplasms (2) · Mesothelioma, Malignant (2) · Small Cell Lung Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms (15) · Neoplasms by Site (11) · Genital Diseases (7) · Neoplasms by Histologic Type (7) · Neoplastic Processes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5)
Specimen Handling (6) · Biopsy (5) · Magnetic Resonance Spectroscopy (4) · X-Rays (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · BAY 1895344 (2) · Cisplatin (2) · Cyclophosphamide (2) · Gemcitabine (2) · Nivolumab (2) · Phantoms, Imaging (2) · Platinum (2) · copanlisib (2) · olaparib (2) · trastuzumab deruxtecan (2)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (3) · Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (18) · Canada (2)
Timothy A Yap (3) · Anthony El-Khoueiry, MD (1) · Aung Naing (1) · Geoffrey I Shapiro (1) · Haiying Cheng (1) · James M Cleary (1) · Janice M Mehnert (1) · Jonathan W Goldman (1) · Jyoti Malhotra (1) · Kanwal P Raghav (1) · Mamta Parikh (1) · Marianna Koczywas (1) · Philip McCarthy, MD (1) · Sarah Shin (1) · Shannon Westin (1)
PMID 28265009, PMID 37036756, PMID 40139261, PMID 41646361, PMID 42847673
UM1CA186688 (4), P30CA072720 (2), U01CA132194 (2), UM1CA186709 (2), UM1CA186716 (2), UM1CA186717 (2), P30CA006516 (1), P30CA014089 (1), P30CA016056 (1), P30CA016672 (1), P50CA093459 (1), R01CA090687 (1), R01CA149627 (1), R01CA164333 (1), U01CA062490 (1)